April 26th 2024
"I think in terms of the 2 large tool sets we have, biomarker testing through urine or blood tests and imaging. I think both are only going to get better," says Jeffrey Tosoian, MD, MPH.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Hypothermia during RARP: No significant benefit seen
June 2nd 2017Although theory and preliminary clinical data indicated that intraoperative regional hypothermia could improve the return to potency and continence after robot-assisted radical prostatectomy, the intervention did not have any significant benefits when put to the more rigorous test of a randomized controlled trial.
Teamwork essential if oral PCa agents are used in office setting
May 19th 2017"The nurse practitioner, nurse, and other ancillary providers who make up the urology team are an essential and valuable asset in the consideration of adding oral androgen receptor inhibitors into the office setting," writes Gwendolyn Hooper, PhD, APRN.
Urologists positive about abiraterone integration
May 19th 2017More than 96% of urologists surveyed said that incorporating abiraterone acetate (ZYTIGA) treatment into practice for patients with metastatic castrate-resistant prostate cancer is easy or manageable after overcoming initial barriers, according to new research presented at the Genitourinary Cancers Symposium in Orlando, FL.
Surveillance rarely used in stage 1, 2 prostate Ca
May 18th 2017While close to 90% of men diagnosed with prostate cancer between 1998 and 2012 had stage 1 and stage 2 disease, more than 90% underwent surgery or radiation to treat the cancer, according to a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Online information linked to PCa treatment regret
May 8th 2017Men who use the Internet as their primary source for prostate cancer treatment decision-making are more likely to regret those decisions a year after treatment than those whose primary sources of information are radiation oncologists or urologists.
ASCO issues guidance on second-line hormonal Tx in CRPC
May 3rd 2017The American Society of Clinical Oncology’s provisional clinical opinion on the use of second-line hormonal therapy for chemotherapy-naïve men with castration-resistant prostate cancer issued by uncovered some surprising findings and issues.
Most men prefer informed decision-making for PCa
April 28th 2017Participants in an outreach event for prostate cancer screening preferred education about prostate cancer prior to undergoing screening, and thought the use of an informed decision-making model was beneficial, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.
Guidelines update: Bladder, kidney, prostate cancer
April 18th 2017This article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.
18F-choline PET/CT detects PCa recurrences early
April 15th 2017Three out of four patients with prostate cancer with an 18F-choline positron emission tomography/computed tomography–detected recurrence were potentially salvageable with local therapy or metastasis-directed therapy (MDT), according to results of the screening phase of the phase II STOMP randomized trial.
Spacer system maintains QoL at 3 years post RT
March 23rd 2017Phase III study results suggest that a hydrogel spacer developed to separate the rectum and prostate during radiotherapy for prostate cancer works to maintain bowel and urinary quality of life and reduces late rectal toxicity by 78% at 3 years post radiotherapy.
Biomarkers predict metastasis, biochemical recurrence
March 22nd 2017Clinicians may soon be able to improve the risk stratification of men with prostate cancer with the help of a genomic classifier or a biopsy-based reverse transcription polymerase chain reaction assay, according to the results of two studies presented at the Genitourinary Cancers Symposium in Orlando, FL.
Novel assay may help identify prostate Bx candidates
March 22nd 2017A simple blood test that measures PSA structure rather than concentration may be more accurate than PSA in identifying men who need a prostate biopsy, according to the results of a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Hypofractionated IMRT outcomes comparable to standard regimen
March 20th 2017“We showed that we can safely compress radiation into a shorter time frame, into fewer treatments, at higher dose per fraction, with similar clinical outcomes and similar toxicity profiles,” said researcher Michael Wang, MD.